Hsbc Holdings PLC Vaxart, Inc. Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.6 - $1.41 $19,243 - $45,222	32,073 New	32,073 $23,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $5.28 $7,965 - $15,576	-2,950 Reduced 4.54%	62,084 $218,000
Q1 2022 May 16, 2022	BUY	$4.29 - $6.64 $1,321 - $2,045	308 Added 0.48%	65,034 $328,000
Q4 2021 Feb 11, 2022	BUY	$5.77 - $7.96 $26,138 - $36,058	4,530 Added 7.53%	64,726 $405,000
Q3 2021 Nov 12, 2021	SELL	$6.67 - $9.8 $8,497 - $12,485	-1,274 Reduced 2.07%	60,196 $479,000
Q2 2021 Aug 13, 2021	BUY	$5.06 - $10.78 $23,959 - $51,043	4,735 Added 8.35%	61,470 $460,000
Q1 2021 May 14, 2021	SELL	$5.64 - $23.33 $37,539 - $155,284	-6,656 Reduced 10.5%	56,735 $343,000
Q4 2020 Feb 12, 2021	BUY	$3.5 - $7.98 $221,868 - $505,860	63,391 New	63,391 $361,000

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.